Clinical Trial

Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

Recruiting

Record status

This record was last updated December 31, 2025 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.

Summary

The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-11-03; most recent amendment 2025-12-30.

Trial Details

NCT Number	NCT07224880
Lead Sponsor	Cytrellis Biosystems, Inc.
Conditions	glp1 Agonist, Gene Expression, Skin Laxity
Enrollment	10 participants
Start Date	2025-10-14
Primary Completion	2026-01-30 (estimated)
Study Completion	2026-02-28 (estimated)
Updated on ClinicalTrials.gov	2025-12-31